HC Wainwright Cuts LifeMD (NASDAQ:LFMD) Price Target to $9.00

LifeMD (NASDAQ:LFMD) had its price objective cut by HC Wainwright from $13.00 to $9.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts also recently commented on the stock. Mizuho dropped their price target on shares of LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday. Lake Street Capital cut their price objective on LifeMD from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday. BTIG Research lowered their price target on LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Finally, KeyCorp dropped their price objective on LifeMD from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Wednesday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, LifeMD presently has an average rating of “Hold” and a consensus target price of $9.43.

LifeMD Stock Performance

Shares of LFMD opened at $3.85 on Wednesday. The firm has a fifty day moving average of $5.88 and a 200-day moving average of $8.59. The company has a market cap of $185.32 million, a price-to-earnings ratio of -22.65 and a beta of 1.57. LifeMD has a 1 year low of $3.43 and a 1 year high of $15.84.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, November 17th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The business had revenue of $60.17 million for the quarter, compared to the consensus estimate of $62.07 million. During the same quarter in the prior year, the firm earned $0.09 EPS. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts predict that LifeMD will post -0.56 EPS for the current year.

Insider Activity

In related news, insider Nicholas P. Alvarez sold 75,000 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total transaction of $444,000.00. Following the transaction, the insider owned 605,000 shares of the company’s stock, valued at approximately $3,581,600. The trade was a 11.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 18.40% of the company’s stock.

Institutional Investors Weigh In On LifeMD

A number of institutional investors have recently added to or reduced their stakes in LFMD. CWM LLC increased its stake in LifeMD by 17.5% during the first quarter. CWM LLC now owns 9,050 shares of the company’s stock valued at $49,000 after acquiring an additional 1,351 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of LifeMD by 148.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock worth $50,000 after acquiring an additional 2,185 shares during the period. Quarry LP acquired a new stake in shares of LifeMD during the 3rd quarter worth approximately $52,000. Tower Research Capital LLC TRC grew its holdings in shares of LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares in the last quarter. Finally, King Wealth Management Group bought a new stake in shares of LifeMD during the third quarter valued at approximately $68,000. 35.52% of the stock is owned by institutional investors and hedge funds.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.